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Abstract
Background: Nitric oxide (NO) and its oxidative reaction products have been repeatedly shown to block steroid
receptor function via nitrosation of zinc finger structures in the DNA-binding domain (DBD). In consequence NO-
donors could be of special interest for the treatment of deregulated androgen receptor(AR)-signaling in castration
resistant prostate cancer (CRPC).
Methods: Prostate cancer (PCa) cells were treated with JS-K, a diazeniumdiolate derivate capable of generating large
amounts of intracellular NO following activation by glutathione S-transferase. Generation of NO was determined
indirectly by the detection of nitrate in tissue culture medium or by immunodetection of nitrotyrosine in the cytoplasm.
Effects of JS-K on intracellular AR-levels were determined by western blotting. AR-dimerization was analyzed by
mammalian two hybrid assay, nuclear translocation of the AR was visualized in PCa cells transfected with a green
fluorescent AR-Eos fusion protein using fluorescence microscopy. Modulation of AR- and WNT-signalling by JS-K was
investigated using reporter gene assays. Tumor cell proliferation following JS-K treatment was measured by MTT-Assay.
Results: The NO-releasing compound JS-K was shown to inhibit AR-mediated reporter gene activity in 22Rv1 CRPC
cells. Inhibition of AR signaling was neither due to an inhibition of nuclear import nor to a reduction in AR-
dimerization. In contrast to previously tested NO-donors, JS-K was able to reduce the intracellular concentration of
functional AR. This could be attributed to the generation of extremely high intracellular levels of the free radical
NO as demonstrated indirectly by high levels of nitrotyrosine in JS-K treated cells. Moreover, JS-K diminished WNT-
signaling in AR-positive 22Rv1 cells. In line with these observations, castration resistant 22Rv1 cells were found to
be more susceptible to the growth inhibitory effects of JS-K than the androgen dependent LNCaP which do not
exhibit an active WNT-signaling pathway.
Conclusions: Our results suggest that small molecules able to inhibit WNT- and AR-signaling via NO-release
represent a promising platform for the development of new compounds for the treatment of CRPC.
Background
Nitric oxide (NO), a free radical gas, is a pleiotropic
molecule critical to a number of physiological and patho-
logical processes. NO-releasing drugs are a growing class
of promising new therapeutics with applications in a
large variety of diseases like cardiovascular and respira-
tory disorders, osteoporosis, Alzheimer’s disease, inflam-
matory lesions and urinary incontinence [1-4]. Moreover
there is increasing evidence that NO donors could have
potential in the prevention and therapy of various malig-
nant tumors like myeloma, breast cancer, ovarian cancer,
pancreatic cancer or prostate cancer (PCa) [5-11].
PCa is the most commonly diagnosed neoplasm in
elderly men and the second cause of cancer related
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advanced PCa is mainly based on androgen ablation
therapies like orchiectomy, systemic administration of
LHRH analog/blocker or anti-androgens. Unfortunately,
the benefit of androgen ablation is only transitory.
Within a few years many PCa progress to a state of the
disease termed castration resistant prostate cancer
(CPRC) where tumor cells grow and survive under sub-
physiological levels of androgens [13]. Although in vitro
the development of a castration resistant phenotype is
mostly based on the loss of the AR in PCa cells, several
clinical studies demonstrated that the AR is rarely lost
in CRPC cells in vivo [14-16]. Indeed, CRPC cells
continue to depend on AR-signalling but bypass the
requirements for physiological levels of circulating
androgens. Various molecular mechanisms that promote
AR-dependent growth of CRPC cells growing under
androgen deprived conditions have been identified: over-
expression/amplification of the AR (hypersensitive path-
way), AR mutations that broaden ligand specificity
(promiscious pathway), AR-activation by non steroid
ligands like growth factors or cytokines (outlaw pathway)
[17] as well as the expression of C-terminally truncated
AR variants lacking vast parts of the ligand binding
domain (LBD). These AR-variants, termed ARΔLBD, are
either products of alternative splicing (AR-V), point
mutations leading to premature stop codons or proteoly-
tic cleavage of the AR protein [18-21]. In contrast to a
full length AR which is activated upon androgenic
stimuli, previous in vitro studies were able to show that
most ARΔLBDs, devoid of a ligand binding domain, are
constitutively active [18-21]. As ARΔLBDs lack most
parts of the LBD situated in the C-terminus of the AR,
they are insensitive to any form of androgen ablation.
Nitric oxide (NO) and its oxidative reaction products
have been repeatedly shown to block nuclear receptors via
nitrosation of their zinc finger structures in the DNA-
binding domain (DBD). The DBD is an essential part of
functional full length AR as well as the constitutively
active ARΔLBDs. In consequence NO-donors could be of
special interest for the treatment of deregulated AR-
signalling in CRPC cells. Inhibition of AR-functions
following treatment with the long living spontaneous NO-
donor (Z)-1-[N-(2-Aminoethyl)-N-(2-ammonioethyl)
amino]diazen-1-ium-1,2-diolat (DETA/NO) has recently
been demonstrated [22]. However, due to the short half-
life of the free radical NO in cell culture medium, rela-
tively high concentrations of DETA/NO were necessary to
induce effects on intracellular nuclear receptors. In order
to generate large amounts of intracellular NO, new
compounds, able to deliver NO in a spatially controllable
manner, are needed. In our study we used the non-ionic,
nitroaromatic diazeniumdiolate JS-K, a glutathione S-
transferase(GST)-activated NO-prodrug able to generate
high intracellular levels of NO in the micromolar range
[23,24].
Studying the effects of JS-K on AR- and WNT-signalling
in the AR-positive PCa cell lines 22Rv1 and LNCaP we
were able to demonstrate that only a 100-fold lower con-
centration of the GST-activated JS-K are necessary to
reach comparable biological effects in PCa cells than the
commonly used DETA/NO that spontaneously generates
NO in physiological fluids. Our data show that NO-
prodrugs, capable of generating large intracellular amounts
of NO, may be suitable for the treatment of advanced
prostate cancer.
Methods
Plasmids, antibodies, chemicals
Probasin promoter driven luciferase-reporter plasmid
(pGL3E-Probasin) was kindly provided by Prof. Dr. Z.
Culig (Innsbruck, Austria). The pARt1EosFP expression
plasmid coding for a green fluorescent AR-Eos fusion
p r o t e i n( A R - E o s F P )w a sag i f tf r o mP r o f .F .O s w a l d
(Ulm, Germany). The CMV-promoter driven b-catenin
expression plasmid pbCAT, containing human b-catenin
cDNA with an activating S33Y mutation was provided
b yD r .H .C l e v e r s( U t r e c h t ,T h eN e t h e r l a n d s ) .T C F -
reporter plasmids pTopFlash (TOP) and pFopFlash
(FOP), containing three copies of wild-type or mutant
TCF-binding sites upstream of a thymidine kinase mini-
mal promoter driving a luciferase gene, were purchased
from Upstate Biotechnology (Lake Placid, NY, USA).
Renilla reniformis luciferase reporter plasmid pRL-tk-
LUC was a product of Promega (Mannheim, Germany).
Mouse monoclonal antibodies directed against beta
actin (ab8224) and nitrotyrosine (ab7048) were products
of Abcam (Cambridge, UK). Mouse monoclonal anti-
body AR441 directed against the N-terminus of the AR
was purchased from Dako (Hamburg, Germany). The
NO-donors O2-(2,4-Dinitrophenyl)-1-[(4-ethoxycarbo-
nyl)piperazin-1-yl]diazen-1-ium-1,2-diolate (JS-K), (Z)-1-
[N-(2-Aminoethyl)-N-(2-ammonioethyl)amino]diazen-1-
ium-1,2-diolate (DETA/NO) and the androgen dihydro-
testosterone (DHT) were a products of Sigma Aldrich
(Taufkirchen, Germany).
Cell culture
22Rv1, LNCaP, DU-145 and PC-3 cells were purchased
from the American Type Culture Collection (Manassas,
VA, USA). LNCaP-SSR, a castration resistant LNCaP
subline [25,26], was a generous gift from Prof. Martin
Burchardt, Greifswald, Germany. 22Rv1, LNCaP, DU-145
and PC-3 were grown in RPMI-1640 (PAA Laboratories
GmbH, Pasching, Austria) supplemented with 10% fetal
bovine serum (FBS) and 1% Penicillin/Streptomycin (Bio-
West, Nuaille, France). LNCaP-SSR were routinely grown
in RPMI-1640, 1% Penicillin/Streptomycin supplemented
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(FBSdcc, BioWest, Nuaille, France) [26].
Transfection and reporter gene assays
22Rv1 cells were grown on 24-well plates (Sarstedt, Nüm-
brecht, Germany). Transfections were performed using
FuGene HD transfection reagent (Roche Diagnostics, Man-
nheim, Germany) according to the manufacturer’s instruc-
tions. AR- and WNT-specific reporter gene assays were
performed as recently described [22,27]. In brief: (1) AR-
signalling: Cells were transfected with 200 ng/well of the
AR-dependent reporter-plasmid pGL3E-Probasin. The
pRL-tk-LUC vector coding for a Renilla luciferase under
control of a constitutively active thymidine kinase promo-
ter was co-transfected (80 ng/well) to correct for transfec-
tion efficiency. After transfection cells were grown in
RPMI 1640 with 5% dextran charcoal treated steroid free,
dextran charcoal treated FBS (FBSdcc; Biowest, Nuaillé,
France) and treated with 5 nM DHT and different concen-
trations of JS-K. (2) WNT-signalling: Luciferase reporter
plasmids pTopFlash (250 ng/well) and pFopFlash (250 ng/
well) were mixed either with pbCAT expression vector
(250 ng/well) or insert-free vector (250 ng/well). pRL-tk-
luc (80 ng/well) was co-transfected to correct for transfec-
tion efficiency. After an incubation period of 12 h in
RPMI-1640 with 5% FBSdcc, medium was changed to
RPMI-1640 containing 2.5% FBSdcc with increasing con-
centrations of JS-K.
AR- and WNT-reporter activities were analyzed after 24
hours using the Dual Luciferase Reporter Assay System
(Promega, Mannheim, Germany). Experiments were
repeated at least three times and performed in triplicates,
unless stated otherwise.
Mammalian two hybrid assay
To investigate the dimerization of the AR we used the
CheckMate/FlexiVector Mammalian Two-Hybrid System
from Promega (Mannheim, Germany). VP16 activation
domain (pFN10A-AR) and Gal4 DNA binding domain
tagged androgen receptor fusion constructs (pFN11A-AR)
were cloned according to the supplier’ss u g g e s t i o n sb y
using pSG5-AR as template. DU-145 and PC-3 cells were
grown in 24-well plates and co-transfected with 150 ng/
well of pFN10A-AR, pFN11A-AR and the Gal4 reporter
construct pGL4.31. After transfection, cells were cultured
and luciferase activities were determined as recently
described [28].
Nuclear Translocation assay
Nuclear translocation of the AR was analyzed in AR-nega-
tive DU-145 and PC-3 cells transfected with the green
fluorescent AR-EosFP [22,29]. Therefore, prostate cancer
cells were transfected in a 24-well plate with pAR-t1EosFP
(0.25 μg/well) for 4 hours in RPMI and allowed to grow
for another 24 hours in RPMI 1640 supplemented with 5%
FBSdcc and antibiotics. Thereafter, cells were grown in
RPMI supplemented with 2.5% FBSdcc in the presence/
absence of 5 nM DHT and JS-K for 6 hours. Localization
of the AR-fusion protein was subsequently analyzed by
fluorescence microscopy.
Western Blot analysis
Proteins were extracted from cells using RIPA buffer as
recently described [30]. Proteins (15 μg lysate) were sepa-
rated by Sodium dodecyl sulfate polyacrylamide gel elec-
trophoresis (SDS-Page). Subsequently proteins were
transferred onto a nitrocellulose membrane (BioTraceNT,
Pall Life Sciences, Dreieich, Germany) by tank blotting
(transfer buffer: 20 mM Tris/HCl, pH 8.7, 150 mM glycine
and 20% (v/v) methanol). Membranes were blocked in
phosphate buffered saline with 0.1% Tween20 (v/v) (PBS-
T )a n d5 %B S A( w / v )f o r1h o u ra tr o o mt e m p e r a t u r e .
The membrane was incubated with the primary antibody
in PBS-T with 1% BSA over night at 4°C. All primary anti-
bodies were used in a dilution of 1:1000, with the excep-
tion of the beta-actin antibody, which was diluted 1:20000.
The membrane was washed with PBS-T three times before
incubating with the peroxidase-coupled secondary anti-
body in a dilution of 1:2000 in PBS-T with 1% BSA. Sig-
nals were visualized by the SuperSignal West Pico
Chemiluminescent Substrate from Pierce (Rockford, USA).
Determination of NO
NO was determined indirectly by the photometric mea-
surement of nitrite according to Green et al. [31]
Immunocytochemistry
For immunocytochemistry 22Rv1 cells were cultured on
glass coverslips (BD Falcon Culture Slides, BD Bios-
ciences) washed (2 × 5 min) with PBS and fixed with
3.7% paraformaldehyd for 15 min at room temperature,
washed (3 × 10 min) in PBS and permeabilized in 0.2%
Triton X-100 with 1% BSA in PBS for 5 min at room
temperature. The cells were washed (3 × 10 min) with
PBS containing 1% BSA. Cells were then incubated with
the monoclonal anti-tyrosine antibody (1:25 in PBS, 1%
BSA for 30 min at 37°C, washed (3 × 10 min and incu-
bated with the mouse monoclonal anti-goat antibody
labeled with Alexa Fluor 488 (Invitrogen, Karlsruhe, Ger-
many, 1:100) for 30 min at 37°C. Cells were then washed
(3 × 10 min), the nuclei stained with DAPI (2.5 μg/ml in
PBS) for 15 min, washed (3 × 10 min) and embedded
with glycine and polyvinyle alcohol 4-88 (Fluka Analyti-
cal, Deisenhofen, Germany).
Cell viability
Cell viability was determined by means of a colorimetric
MTT-assay measuring the reduction of the water
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derivative by functional mitochondria [32,33].
Statistical Analysis
Data are reported as means ± standard deviation. Analy-
sis was performed with Student’s T-test (two tailed for
independent samples) with p < 0.05 considered as
significant.
Results
JS-K induces nitrosation of tyrosine residues in cellular
proteins
I nap r e v i o u sp a p e rN Og e n e r a t e db yD E T A / N Ow a s
shown to nitrosate tyrosine residues in proteins to
nitrotyrosine [22]. Therefore, we tested JS-K’s ability to
nitrosate proteins via intracellular NO-release. In order
to generate a control substance without the NO-releas-
ing moiety, we took advantage of the observation that
sera of patients were repeatedly shown to possess low
GST-activity [34,35]. In our experiment 5 μMJ S - Kw a s
incubated at 37°C in RPMI-1640 supplemented with
10% FBS. Generation of NO in the medium was mea-
sured indirectly by the determination of nitrite. Under
these conditions maximal medium nitrite levels were
detectable after nine to twelve hours (Figure 1A). The
remaining inactive JS-K metabolites S-(2, 4-Dinitrophe-
nyl)-glutathione and 4-carboxy-piperazine [23] were
subsequently used as a negative control and termed
JS-Kneg.
Incubation with 2 μMJ S - Ka sw e l la s2 0 0μMD E T A /
NO (serving as positive control) led to a nitrosation of
intracellular proteins as shown by fluorescescence micro-
scopy of nitrotyrosine residues (Figure 1B). In contrast,
neither untreated cells nor cells treated with the control
solution JS-Kneg harbouring the inactive JS-K metabolites,
showed any nitrotyrosine staining (Figure 1B).
JS-K inhibits AR-mediated genomic function in 22Rv1
cells
To test whether JS-K influences the transcriptional
activity of the AR, we transiently co-transfected AR-
positive 22Rv1 human prostate cancer cells with
pGL3E-Pro, an androgen-responsive probasin-promoter
driven reporter plasmid, and pRL-tk-Luc, a Renilla luci-
ferase plasmid under control of a constitutively active
thymidine kinase promoter (control of transfection effi-
ciency). Subsequently cells were incubated for 44 hours
with 5 nM DHT and increasing concentrations of JS-K
or JS-Kneg. JS-K significantly inhibited DHT-induced
AR-transactivation in a dose-dependent manner. Inhibi-
tion was already significant at a concentration of 2 μM
JS-K. In contrast, JS-Kneg was unable to diminish AR
transcriptional activity even at higher concentrations
(Figure 2).
JS-K does not modulate dimerization or nuclear
localization of the AR
In vitro NO has been shown to repress vitamin D3 sig-
nalling through inhibition of vitamin D receptor (VDR)
- retinoic X receptor (RXR)-heterodimerization [36]. To
test whether JS-K can inhibit AR-homodimer formation
in vivo, we performed an AR-specific mammalian two
hybrid (M2H)-assay in AR-negative PC-3 and DU-145
cells (Figure 3, Additional File 1). As seen in Figure 3,
JS-K was unable to repress DHT-induced AR-homodi-
merization at concentrations that were already sufficient
to inhibit AR-transactivation (Figures 3 and 2).
In order to test whether high NO concentrations are
able to influence the nuclear translocation of the AR, we
transfected the AR-negative PC-3 with a construct coding
for a green fluorescent AR-Eos fusion protein (AR-EosFP)
[22,37]. Subsequently cells were grown for six hours in the
presence/absence of 5 nM DHT with or without JS-K or
JS-Kneg. Under hormone-free conditions the AR was pre-
dominantly located in the cytoplasm (> 80%) whereas in
presence of DHT the AR was transported to the nucleus
Figure 1 Release of NO from JS-K. (A) Generation of NO from JS-
K in RPMI-1640 medium containing 10% fetal bovine serum was
determined indirectly by photorimetric detection of nitrite
according to Green et al. [31]. (B) Detection of nitrotyrosine by
fluorescence microscopy in 22Rv1 cells: Generation of intracellular
NO was detected indirectly by detection of nitrotyrosine (green).
Cell nuclei were stained with DAPI. [A] untreated cells, [B] 2 μM JS-
Kneg, [C] 2 μM JS-K, [D] 200 μM DETA/NO.
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centration 4 μM) was unable to reverse the nuclear locali-
zation of the AR in DHT treated PC-3 cells (82% ± 2% to
78 ± 2%). In a complementary experiment transfection of
AR negative DU-145 cells with AR-EosFP yielded similar
results (Additional File 2).
JS-K leads to a down-regulation of the AR-protein
In contrast to the commonly used spontaneous NO-donor
DETA/NO which generates NO in aquaeous solutions,
JS-K is able to generate high amounts of NO within target
cells after enzymatic activation by GST. The profound dif-
ferences in local NO-production prompted us to analyze
the effects of JS-K on the AR-concentration in the prostate
cancer line 22Rv1 and LNCaP. Both cell lines express
functional AR-proteins. Whereas 22Rv1 cells express a
120 kDa AR-isoform as well as a C-terminally truncated,
constitutively active 79 kDa AR-V splicing variant [38] the
LNCaP cells express a full length AR (119 kDa) with a
point mutation at position 877 (T877A) [39]. Treatment
with JS-K for 30 hours diminished the amount of all AR-
forms in 22Rv1 as well as in LNCaP cells (Figure 5). The
downregulation of the AR in LNCaP was less pronounced
than the dramatic decrease of AR and AR-V in 22Rv1 cells
(Figure 5). In both cell lines incubation with JS-Kneg had
no influence on intracellular AR-levels (Figure 5).
JS-K inhibits WNT/b-catenin signaling in 22Rv1 cells
Interaction of the canonical WNT/b-Catenin pathway
with the AR is thought to promote progression of PCa
to the terminal castrate-resistant stage [40]. Crosstalk
between the canonical WNT and AR-pathways occurs
at several levels: (a) b-Catenin interacts with the AR to
increase its transcriptional activity [27], (b) WNT-signal-
ling influences AR-signalling through its ability to regu-
late AR-mRNA as well as AR-stability [41].
Several lines of evidence indicate that NO is involved in
the regulation of the WNT/b-catenin pathway in various
tumors [42-44]. A common approach to analyze the cano-
nical WNT-pathway in vitro is the over-expression of
mutated stabilized b-catenin (S33Y) that activate TCF/
LEF-dependent reporter gene constructs [27]. As LNCaP
cells are unable to activate b-catenin dependent reporter
gene expression [27] we tested the effects of JS-K on the
canonical WNT-pathway in 22Rv1 cells. As seen in Figure
6, JS-K was able to diminish b-catenin signalling in the
CRPC cell line 22Rv1 in a dose dependent manner. Down-
regulation of the canonical WNT-pathway was already
significant at JS-K concentrations of 1 μM( r e d u c t i o no f
transcriptional activity: 42 ± 8%, p < 0.01).
Growth inhibitory effects of JS-K are most pronounced in
castration resistant prostate cancer cells
Based on our observations we tested the antiproliferative
effects of JS-K on prostate cancer cell lines. JS-Kneg served
as negative control. Cellular proliferation was assessed by
Figure 2 JS-K inhibits AR-dependent reportergene activity in 22Rv1 cells. Cells were cotransfected with a probasin reporter gene plasmid
and a Renilla luciferase plasmid serving as transfection control. Subsequently cells were grown in presence/absence of 5 nM DHT. Reportergene
activity was determined using the Dual Luciferase Assay System from Promega. Data are presented as fold of untreated controls ± standard
deviation (SD). Results are mean values of three independent experiments performed in quadruplicates: *p < 0.05; **p < 0.01.
Figure 3 JS-K does not inhibit AR-dimerization in presence of
androgens. AR-dimerization was determined in PC-3 cells using the
CheckMate Mammalian Two-Hybrid System from Promega as
described in Material and Methods. Results are mean values of four
independent experiments performed in quadruplicates.
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tion of tetrazolium salts to formazan derivatives by func-
tional mitochondria [32,33]. Although redox sensitive
viability assays have some limitations depending on the
chemical nature of the compounds to be evaluated [45]
they are widely used for measuring cell viability following
nitrosative or oxidative stress [22,46,47]. The suitability of
this method was furthermore documented by a previous
study analyzing the effects of the spontaneous NO-donor
DETA/NO on the viability of PCa-cells. Comparison of
MTT with three commonly used methods to measure cell
proliferation, i.e quantification of intracellular ATP, trypan
blue dye exclusion and neutral red assay were found to
generate similar results [22].
A first series of experiments indicated that castration
resistant 22Rv1 cells were more susceptible to the growth
inhibitory effects of JS-K than the androgen sensitive
LNCaP cells (Figure 7A). Maximal growth inhibitory
effects were achieved at a concentration of 4 μM JS-K for
22Rv1 (growth inhibition 50 ± 6%, p < 0.05) and 4 μM
JS-K for LNCaP (growth inhibition 23 ± 9%).
Given the highly divergent nature of the AR-positive
cell lines 22Rv1 and LNCaP we repeated the proliferation
experiments using the androgen sensitive LNCaP and
LNCaP-SSR, an AR-positive castration resistant LNCaP-
subline. The AR-negative DU-145 served as control (AR
Figure 4 NO does not influence hormone-induced nuclear translocation of the AR. Prostate cancer cells (PC-3) expressing a green
fluorescent AR-EosFP [37] were incubated for 6 hours in the absence/presence of DHT and JS-K/JS-Kneg. Intracellular localization of AR-EosFP
was determined by fluorescence microscopy: (A) untreated controls, (B) 5 nM DHT, (C) 5 nM DHT and 4 μM JS-K, (D) 5 nM DHT and 4 μM JS-
Kneg. Bars: Data presented in % cellular localization ± SD. Results are mean values of three independent experiments performed in
quadruplicates.
Figure 5 Influence of JS-K and JS-Kneg on the androgen
receptor concentration in human prostate cancer cells. 22Rv1
and LNCaP cells were incubated for 30 hours with or without 5 nM
dihydrotestosterone in the presence of JS-K or JS-Kneg. Subsequently
cells were lysed and separated by SDS-electrophoresis (15 μg
protein per lane). Proteins were transferred onto a nitrocellulose
membrane. AR and b-actin (loading control) were visualized by
immunodetection.
Figure 6 JS-K diminishes WNT-signalling in 22Rv1 cells.2 2 R v 1
cells were co-transfected with an expression vector for mutated,
stabilized b-catenin together with either the TCF reporter construct
TOP or FOP as recently described [25]. Data are presented as fold of
untreated controls (TOP/FOP) ± SD, **p < 0.01, ***p < 0.001.
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LNCaP-SSR cells were more susceptible to the growth
inhibitory effects (growth inhibition at 1 μMJ S - K3 1±
2%, p < 0.01) than the parental LNCaP cells (growth inhi-
bition at 4 μM JS-K 33 ± 1%, p < 0.01) (Figure 7B). In
contrast to the AR-positive LNCaP and LNCaP-SSR the
AR-negative DU-145 were less susceptible to the growth
inhibitory effects of JS-K (growth inhibition at 4 μM JS-K
17 ± 9%).
Discussion
Current treatment for advanced PCa is mainly based on
androgen ablation therapies like chemical or surgical cas-
tration or application of anti-androgens. Although hor-
monal therapy is initially very effective, the benefit of
androgen withdrawal is only transitory. While still
expressing high levels of functional AR, some PCa cells
acquire the ability to grow and survive under castrate
levels of circulating androgens. The mechanisms involved
in an altered AR-signalling of CRPC cells include an
over-expression/amplification of the AR (hypersensitive
pathway), point mutations broadening ligand-specificity
of the receptor (promiscuous pathway) as well as activa-
tion of the AR by peptide growth factors or cytokines
(outlaw pathway) [17]. A recently identified mechanism
enabling CRPC cells to bypass the requirements for phy-
siological levels of androgens is the expression of C-term-
inal truncated, constitutively active AR splicing variants
termed AR-V. Due to the loss of the C-terminus, AR-Vs
are lacking essential parts of the ligand binding domain
[21]. In the absence of androgens, AR-Vs were shown to
induce AR-signalling either as AR-V/AR-V-homodimers
or AR-V/AR-heterodimers [18,48]. Whereas AR-V/AR-V
homodimers are unaffected by hormone ablation in gen-
eral, some AR-V/AR-heterodimers were insensitive to
the commonly used anti-androgens [48]. Given the fact
that both, AR wild type as well as AR-V, play a crucial
role in a high percentage of CRPC there is an urgent
need for an AR-blockade that does not involve the LBD.
Nitric oxide, a free radical gas, has been repeatedly
shown to impair the function of nuclear receptors via tar-
geting their cys4-type zinc fingers, located in the DBD of
these receptors [49]. This is well exemplified by studies
showing a NO-induced nitrosation of the cystein residues
within the zinc finger structures of steroid receptors like
the estrogen receptor (ER) [50]. As the DBD is a crucial
part of functional full length AR as well as constitutively
active AR-Vs, it is tempting to speculate that NO-donors
able to release NO in a spatial and timely controllable
manner could be of special interest for the treatment of
deregulated AR-signalling in CRPC cells.
Inhibitory effects of NO on AR-function in PCa cells
was first described in vitro using the spontaneous NO-
donor Deta/NO [22]. In a recent clinical study Siemens
et al. were able to show an increase of the PSA doubling
time in patients treated with the NO-donor glyceryl trini-
trate (GTN) [51]. No cardiovascular toxicities or serious
side effects were encountered during treatment with
GTN [51]. Although the number of patients enrolled in
the study was relatively low (29 patients), our data and
the clinical data with GTN [22,51] support the assump-
tion that NO might be suitable for the treatment of
advanced PCa.
Commonly used NO-Donors like Deta/NO, sponta-
neously dissociate in a pH dependent process thereby
releasing the free radical NO. Unfortunately NO exhibits
only a relatively short half-life in the tissue culture med-
ium or body fluids. Therefore, we tested a potent NO-
prodrug, the non-ionic nitroaromatic diazeniumdiolate
Figure 7 Effects of JS-K on the proliferation of prostate cancer
cells. (A) 22Rv1 cells are more susceptible to the growth inhibitory
effects of JS-K than the androgen sensitive LNCaP cells Cells were
cultured in the absence/presence of increasing concentrations of JS-
K (1,2,4 μM) or JS-Kneg (4 μM). Cell viability was determined after 96
hours by a colorimetric MTT assay. Results are mean values of four
independent experiments performed in quadruplicates. Data are
presented as % of untreated controls ± SD, *p < 0.05. (B) Effects of
JS-K on the AR negative DU-145 and the AR-positive LNCaP
(hormone sensitive) and LNCaP-SSR (castration resistant). Cells were
cultured in the absence/presence of increasing concentrations of JS-
K (1, 2, 4 μM) or JS-Kneg (4 μM). Cell viability was determined after
96 hours by a colorimetric MTT assay. Results are mean values of
four independent experiments performed in quadruplicates.
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tathione S-transferase (GST), a key phase II detoxifica-
tion enzyme that is frequently over-expressed in cancer
tissue. Among the various isoforms of GSTs which are
located in the cytoplasm and the mitochondria, mainly
the π isoform is able to form the so called < Meisenhei-
mer complex >[52] which finally delivers NO directly
within the cell. First experimental in vivo studies using
tumor xenografts in a mouse model, showed that JS-K
exhibits a strong anti-tumor activity and is generally
well tolerated by the host organism [5,23,24].
In order to test the effects of JS-K on AR signalling, we
treated the AR-positive CRPC cell line 22Rv1 grown in
presence of DHT with increasing concentrations of JS-K.
Generation of intracellular NO was monitored indirectly
by detection of nitrotyrosine using fluorescence micro-
scopy. JS-K was able to inhibit the genomic functions of
the AR in 22Rv1 cells. The inhibition of AR-signalling was
neither due to an inhibition of AR-dimerization nor to an
inhibition of nuclear translocation. Interestingly, JS-K was
able to diminish intracellular levels of all AR-isoforms in
PCa cells. However, in contrast to the dramatic downregu-
lation of AR-V and AR in 22Rv1 cells the intracellular AR
levels of LNCaP were only slightly affected.
So far, studies on intracellular steroid receptor levels
following NO-treatment are sparse. In a previous study
using Deta/NO as an NO-donor the concentration of the
endogenous AR in LNCaP remained unaffected [22]. In
contrast, DETA/NO was able to downregulate the intra-
cellular levels of the Drosophila melanogaster ecdysteroid
receptor (EcR) when overexpressed in chinese hamster
o v a r yc e l l s ,C H O - K 1[ 5 3 ] .A l t h o u g ht h eh e t e r o l o g e o u s
expression of an insect steroid receptor in CHO-K1 cells
differs largely from the situation found in LNCaP cells
that express high levels of intracellular AR under physio-
logical conditions the present data suggest that there are
cell specific differences in the sensitivity of cells towards
NO-treatment. Moreover, the generation of NO by JS-K
largely depends on the intracellular GST-activity that dif-
fers between different cell lines or cell types.
The fact that NO is able to inhibit the canonical WNT-
pathway in different tumor cells [42-44] including pros-
tate cancer cells (as seen in this study) offers a more
intriguing explanation for the massive down regulation of
AR and AR-V in 22Rv1 cells. There is experimental evi-
dence that the WNT/b-catenin-pathway is able to up-
regulate AR-mRNA expression in prostate cancer cell
lines through interaction with TCF/LEF binding sites
situated in the promoter region of the AR [41]. In con-
trast to the highly aggressive castration resistant 22Rv1
cells which are able to drive a WNT-typical T-cell factor
(TCF)-dependent reporter gene activity, the androgen
s e n s i t i v eL N C a Pa r eu n a b l et od os o[ 2 7 ] .I nc o n s e -
quence, the inhibition of the canonical WNT-pathway
would lead to a decrease of AR and AR-V mRNA in
22Rv1 cells but not or to a lesser extent in LNCaP.
In proliferation assays castration resistant 22Rv1 and
LNCaP-SSR cells were more susceptible to the growth
inhibitory effects of JS-K than LNCaP. Whereas LNCaP
cells largely depend on androgenic stimuli, the 22Rv1
and LNCaP-SSR cells are able to grow under androgen
deprived conditions. LNCaP cells express a full length
AR with a point mutation at position 877 (T877A),
enabling the AR to be stimulated by different steroids
(promiscuous AR) [39]. In contrast to the hormone
dependent LNCaP, the castration resistant LNCaP-SSR
cells were shown to exhibit high levels of nuclear AR in
the absence of hormonal stimuli [26]. Increased nuclear
AR-levels were paralleled by elevated PSA-levels sug-
gesting that the AR is active in these cells [26]. In
22Rv1 cells two AR-forms can be found: A larger AR-
form expressing 3 zinc finger motifs due to the duplica-
tion of exon 3 (AR
Ex3dup) and a C-terminally truncated,
constitutively active AR-V [20]. In the absence of andro-
genic stimuli, some AR-Vs have been shown to form
constitutively active AR-V-homodimers or AR/AR-V-
heterodimers, thereby uncoupling the need of CRPC
cells for physiological levels of androgens [18,48].
Although it is unknown whether AR
Ex3dup is able to
form androgen independent heterodimers with AR-V in
22Rv1 cells, its expression of 3 zinc finger structures
makes it probably also more susceptible to the effects of
NO. The fact that NO targets the zinc finger structures
of wild type AR, mutated AR-forms as well as AR-Vs
suggests that NO-donors are promising compounds for
the treatment of deregulated AR-activity. Moreover, the
observation that CRPC cells like 22Rv1 or LNCaP-SSR,
expressing either constitutively active AR-Vs or func-
tionally deregulated full length AR, are more susceptible
to the effects of JS-K than LNCaP cells further supports
this assumption.
Conclusions
From our in vitro studies we conclude that GST-acti-
vated NO-prodrugs like JS-K show features which might
be suited for the treatment of advanced PCa. Therapies
targeting the AR and the canonical WNT pathway may
lead to a more efficient treatment of CRPC. Therefore,
compounds like JS-K may serve as leader compounds
for the development of NO-based therapeuticals, target-
ing key structures in castration resistant prostate cancer
cells.
Additional material
Additional file 1: Figure 1S: JS-K does not inhibit AR-dimerization.
Complementary data to experiment presented in Figure 3: AR-
dimerization was determined in DU-145 cells using the CheckMate
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Page 8 of 10Mammalian Two-Hybrid System described in Material and Methods.
Results are mean values of three independent experiments performed in
quadruplicates. (DOC 20 kb).
Additional file 2: Figure 2S: NO does not influence hormone-
induced nuclear translocation of AR-EosFP in DU-145.
Complementary data to experiment presented in Figure 4. (TIFF 1541 kb).
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